EIKN — Eikon Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $534.44m
- $198.47m
Annual balance sheet for Eikon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 430 | 220 | 336 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 436 | 228 | 349 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 86.9 | 259 | 234 |
| Other Long Term Assets | |||
| Total Assets | 526 | 491 | 595 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 31.4 | 56.4 | 55 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 58.9 | 255 | 312 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 467 | 236 | 282 |
| Total Liabilities & Shareholders' Equity | 526 | 491 | 595 |
| Total Common Shares Outstanding |